BioLineRx (NASDAQ:BLRX) had its target price boosted by Maxim Group from $5.00 to $10.00 in a note issued to investors on Tuesday, The Fly reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price target would indicate a potential upside of 114.13% from the company’s previous close.
Several other research analysts also recently issued reports on the stock. HC Wainwright reduced their price target on shares of BioLineRx from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday, March 1st. Zacks Investment Research downgraded shares of BioLineRx from a “hold” rating to a “sell” rating in a research report on Wednesday, February 24th.
NASDAQ BLRX traded up $1.48 on Tuesday, hitting $4.67. 7,440,859 shares of the company were exchanged, compared to its average volume of 1,608,911. The firm has a 50 day moving average of $2.90 and a two-hundred day moving average of $2.71. The company has a market cap of $199.84 million, a P/E ratio of -2.06 and a beta of 2.08. The company has a current ratio of 2.05, a quick ratio of 2.04 and a debt-to-equity ratio of 0.14. BioLineRx has a 1-year low of $1.40 and a 1-year high of $4.23.
Large investors have recently made changes to their positions in the stock. Rhumbline Advisers acquired a new stake in shares of BioLineRx in the 4th quarter valued at approximately $36,000. Thomasville National Bank raised its position in shares of BioLineRx by 62.6% in the 4th quarter. Thomasville National Bank now owns 20,325 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 7,825 shares during the period. Game Plan Financial Advisors LLC acquired a new stake in shares of BioLineRx in the 1st quarter valued at approximately $74,000. LPL Financial LLC raised its position in shares of BioLineRx by 154.1% in the 4th quarter. LPL Financial LLC now owns 42,876 shares of the biotechnology company’s stock valued at $108,000 after acquiring an additional 26,000 shares during the period. Finally, Morgan Stanley raised its position in shares of BioLineRx by 36.0% in the 3rd quarter. Morgan Stanley now owns 768,335 shares of the biotechnology company’s stock valued at $1,260,000 after acquiring an additional 203,221 shares during the period. Institutional investors and hedge funds own 17.46% of the company’s stock.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.
Read More: Tariff
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.